Evolent Health (EVH) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Core Insights - Evolent Health reported a revenue of $444.33 million for the quarter ended June 2025, marking a year-over-year decline of 31.3% and an EPS of -$0.10 compared to $0.30 a year ago, indicating significant financial challenges [1] - The revenue fell short of the Zacks Consensus Estimate of $457.4 million by 2.86%, and the EPS was below the consensus estimate of $0.09 by 211.11% [1] Financial Performance - Evolent Health's stock has returned -16.7% over the past month, contrasting with the Zacks S&P 500 composite's +1.2% change, suggesting underperformance relative to the broader market [3] - The company currently holds a Zacks Rank 3 (Hold), indicating it may perform in line with the market in the near term [3] Key Metrics Analysis - Average PMPM Fees / Revenue per Case for Performance Suite was $13.76, below the estimated $14.21 [4] - Average PMPM Fees / Revenue per Case for Specialty Technology and Services Suite was $0.35, slightly below the estimated $0.36 [4] - Average PMPM Fees / Revenue per Case for Administrative Services was $15.13, compared to the estimated $15.82 [4] - Average Lives on Platform / Cases for Cases was 13 thousand, below the estimated 14.39 thousand [4] - Average Lives on Platform / Cases for Performance Suite was 6.49 million, slightly above the estimated 6.48 million [4] - Average Lives on Platform / Cases for Specialty Technology and Services Suite was 77.02 million, below the estimated 77.71 million [4] - Average Lives on Platform / Cases for Administrative Services was 1.23 million, slightly above the estimated 1.22 million [4] - Average PMPM Fees / Revenue per Case for Cases was $2,969.00, below the estimated $3,008.56 [4]